Zevra Therapeutics (NASDAQ:ZVRA) Rating Lowered to Hold at Wall Street Zen

Zevra Therapeutics (NASDAQ:ZVRA) was downgraded by stock analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued on Saturday.

A number of other equities analysts have also commented on the stock. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Zevra Therapeutics in a research note on Saturday, September 27th. Citigroup reaffirmed an “outperform” rating on shares of Zevra Therapeutics in a research note on Wednesday, August 13th. JMP Securities decreased their price objective on shares of Zevra Therapeutics from $19.00 to $18.00 and set a “market outperform” rating for the company in a research note on Wednesday, August 13th. Cantor Fitzgerald boosted their price objective on shares of Zevra Therapeutics from $25.00 to $29.00 and gave the company an “overweight” rating in a research report on Thursday, July 10th. Finally, HC Wainwright initiated coverage on shares of Zevra Therapeutics in a research report on Wednesday, July 2nd. They set a “buy” rating and a $26.00 price objective on the stock. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Zevra Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $24.00.

Zevra Therapeutics Trading Up 4.7%

Zevra Therapeutics stock opened at $9.75 on Friday. The company has a 50 day moving average price of $9.44 and a 200 day moving average price of $8.99. Zevra Therapeutics has a 52 week low of $6.19 and a 52 week high of $13.16. The company has a debt-to-equity ratio of 0.52, a quick ratio of 7.81 and a current ratio of 7.85. The firm has a market capitalization of $547.27 million, a price-to-earnings ratio of -46.43 and a beta of 1.49.

Insider Buying and Selling at Zevra Therapeutics

In other news, Director John B. Bode acquired 5,000 shares of Zevra Therapeutics stock in a transaction dated Tuesday, August 19th. The stock was acquired at an average cost of $9.16 per share, for a total transaction of $45,800.00. Following the completion of the purchase, the director owned 45,000 shares of the company’s stock, valued at $412,200. This represents a 12.50% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 2.40% of the company’s stock.

Institutional Trading of Zevra Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Ameritas Investment Partners Inc. lifted its stake in shares of Zevra Therapeutics by 30.0% in the second quarter. Ameritas Investment Partners Inc. now owns 5,541 shares of the company’s stock worth $49,000 after buying an additional 1,280 shares during the last quarter. GAMMA Investing LLC lifted its stake in shares of Zevra Therapeutics by 20,564.1% in the first quarter. GAMMA Investing LLC now owns 8,059 shares of the company’s stock worth $60,000 after buying an additional 8,020 shares during the last quarter. Tower Research Capital LLC TRC lifted its stake in shares of Zevra Therapeutics by 617.5% in the second quarter. Tower Research Capital LLC TRC now owns 9,937 shares of the company’s stock worth $88,000 after buying an additional 8,552 shares during the last quarter. Creative Planning acquired a new position in Zevra Therapeutics during the 2nd quarter valued at $92,000. Finally, Fox Run Management L.L.C. acquired a new position in Zevra Therapeutics during the 2nd quarter valued at $99,000. 35.03% of the stock is currently owned by institutional investors and hedge funds.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.